Determination of .beta..sub.2 -microglobulin in human urine and serum by latex immunoassay

• US 4,329,152 A
• Filed: 10/06/1980
• Issued: 05/11/1982
• Est. Priority Date: 10/06/1980
• Status: Expired due to Term

• Current Assignee: International Lead Zinc Research Organisation Inc.
• Original Assignee: International Lead Zinc Research Organisation Inc.
• Inventors: Lauwerys, Robert R., Bernard, Alfred M.
• Primary Examiner(s): Marantz, Sidney
• Application Number:
  US06/194,268
• Time in Patent Office: 582 Days
• Field of Search: 23/230 B, 424/12, 422/64, 422/73
• US Class Current: 436/534
• CPC Class Codes: G01N 33/54313 the carrier being characterised by its particulate form
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

A highly sensitive method has been developed for the determination of β₂ -microglobulin in human urine or serum samples. This method is based on the agglutination of β₂ -microglobulin by latex particles coated with an anti-body against β₂ -microglobulin in a stabilizing solution.

Claims

1. A method for determining β

₂ -microglobulin concentration in a human urine or serum sample comprising the steps of;

(a) coating latex particles with an antibody against the β

₂ -microglobulin;

(b) incubating the antibody-coated particles diluted in a stabilizing solution with the sample so as to permit the β

₂ -microglobulin to agglutinate a proportion of the particles, said proportion being related to the concentration of β

₂ -microglobulin in the sample; and

(c) quantitating the unagglutinated particles and thereby determining the β

₂ -microglobulin concentration in the sample.

2. A method according to claim 1, wherein the stabilizing solution consists of glycine buffered saline containing bovine serum albumin.

3. A method according to claim 2, wherein said stabilizing solution is adjusted to about pH 10.

4. A method according to claim 1 or 2 wherein the latex particles are coated with antibody against the β

₂ -microglobulin by the following steps;

(a) diluting the antibody with glycine buffered saline;

(b) adding the latex particles to the diluted antibody with agitation; and

(c) precipitating the latex particles followed by the redispersement of the latex particles in glycine buffered saline;

the resulting antibody-coated latex particles being suitable for long-term storage.